AUS
NZ
UK
CA
USA
IND
Highlights:
- Phase 2a study initiated for PTX-100 in rare Cutaneous T-Cell Lymphoma
- Trial spans Australia, US, and Europe with up to 40 patients
- PTX-100 targets unmet need in relapsed or refractory CTCL
Prescient Therapeutics (ASX:PTX) has reached a significant milestone by dosing the first patient in its Phase 2a clinical trial for PTX-100, a novel treatment designed for relapsed or refractory Cutaneous T-Cell Lymphoma (CTCL). This rare form of non-Hodgkin lymphoma affects the skin by allowing malignant T cells to multiply, often causing chronic and debilitating symptoms. PTX-100 is being explored as a promising new option where current treatments are limited.
The open-label Phase 2a study aims to evaluate two dosage levels of PTX-100 across multiple sites in Australia, the United States, and Europe. Up to 40 patients will be enrolled to assess the drug’s effectiveness as the primary objective, with safety as a key secondary consideration. This trial represents an important step forward in addressing a critical unmet clinical need for patients with difficult-to-treat CTCL.
PTX-100 works by inhibiting geranylgeranyl transferase-1 (GGT-1), an enzyme involved in cancer cell survival pathways. By disrupting these pathways, the treatment hopes to offer a first-in-class therapy for this rare cancer. Previous studies have shown encouraging signs of safety and clinical activity, which led the U.S. Food and Drug Administration (FDA) to grant PTX-100 both Orphan Drug Designation for all T-cell lymphomas and Fast Track Designation for relapsed or refractory mycosis fungoides, the most common CTCL subtype.
As Prescient Therapeutics advances this promising therapy, it reflects growing innovation among companies within the ASX200. Investors interested inASX dividend stocks often look toward the broader market trends driven by biotech and healthcare advancements, such as those spearheaded by Prescient.
The trial is currently recruiting patients, with ongoing developments expected to provide further insights into PTX-100’s potential. Prescient Therapeutics will share updates during a live briefing scheduled for 29 May, offering a detailed view of the PTX-100 program and other projects within its pipeline.
With such progress underway, Prescient (PTX) continues to position itself within the innovative landscape of the ASX200, contributing to the broader narrative of emerging therapies that could transform treatment outcomes in rare cancers.
